Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross …
CR Jack, HJ Wiste, SD Weigand, WA Rocca… - The Lancet …, 2014 - thelancet.com
Summary Background As preclinical Alzheimer's disease becomes a target for therapeutic
intervention, the overlap between imaging abnormalities associated with typical ageing and …
intervention, the overlap between imaging abnormalities associated with typical ageing and …
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a …
CR Jack, HJ Wiste, SD Weigand, TM Therneau… - The Lancet …, 2017 - thelancet.com
Background A new classification for biomarkers in Alzheimer's disease and cognitive ageing
research is based on grouping the markers into three categories: amyloid deposition (A) …
research is based on grouping the markers into three categories: amyloid deposition (A) …
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study
CR Jack, TM Therneau, HJ Wiste, SD Weigand… - The Lancet …, 2016 - thelancet.com
Background In a 2014 cross-sectional analysis, we showed that amyloid and
neurodegeneration biomarker states in participants with no clinical impairment varied …
neurodegeneration biomarker states in participants with no clinical impairment varied …
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
Background Improved understanding is needed of risk factors and markers of disease
progression in preclinical Alzheimer's disease. We assessed associations between brain β …
progression in preclinical Alzheimer's disease. We assessed associations between brain β …
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
VL Villemagne, S Burnham, P Bourgeat… - The Lancet …, 2013 - thelancet.com
Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …
Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the …
Background Some people with substantial Alzheimer's disease pathology at autopsy had
shown few characteristic clinical symptoms or signs of the disease, whereas others with little …
shown few characteristic clinical symptoms or signs of the disease, whereas others with little …
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences
Objective: Several lines of evidence suggest that pathologic changes underlying Alzheimer
disease (AD) begin years prior to the clinical expression of the disease, underscoring the …
disease (AD) begin years prior to the clinical expression of the disease, underscoring the …
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study
Background The biomarker model of Alzheimer's disease postulates a dynamic sequence of
amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from …
amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from …
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease …
Background Brain amyloid β (Aβ) deposition and neurodegeneration have been
documented in about 50–60% of cognitively healthy elderly individuals (aged 60 years or …
documented in about 50–60% of cognitively healthy elderly individuals (aged 60 years or …
Predicting Alzheimer disease with β‐amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
Objective Biomarkers for Alzheimer disease (AD) can detect the disease pathology in
asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their …
asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their …